Mumbai-based Cipla announced plans to build a $89 million biosimilar manufacturing plant in the coastal city of Durban.
The Cipla BioTec plant -- the first South African facility for Cipla's biotechnology arm -- will manufacture biosimilars at lower costs for South Africa. There is also potential to export to the U.S., Europe and Asia, said the company.
Construction for the new facility is scheduled to start in early 2017, with full operations expected to commence in the third quarter of 2018.
Read the Business Standard coverage